SCHEMBL1614081

SCHEMBL1614081

COCCn1cc(-c2nc(N)ncc2Cl)c2cc(C#CC3(O)CCCC3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAK4 O96013 3/20 0.45
▸ PAK1 Q13153 1/20 0.45
▸ PAK2 Q13177 1/20 0.45
▸ PKN1 Q16512 1/20 0.45
▸ PAK6 Q9NQU5 1/20 0.45
▸ PAK5 Q9P286 1/20 0.45
▸ DYRK1A Q13627 1/20 0.43
▸ CCNT1 O60563 1/20 0.42
▸ CDK7 P50613 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ CCNH P51946 1/20 0.42
▸ MNAT1 P51948 1/20 0.42
▸ CHUK O15111 3/20 0.39
▸ MAP3K14 Q99558 7/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ NR2F2 P24468 1/20 0.39
▸ PIKFYVE Q9Y2I7 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1614094 0.95 PAK4 (0.43) PAK4PAK1PAK2PKN1PAK6
SCHEMBL1614097 0.95 PAK4 (0.44) PAK4PAK1PAK2PKN1PAK6
SCHEMBL12714662 0.90 CHUK (0.41) PAK4PAK1PAK2PKN1PAK6
SCHEMBL1614037 0.90 MAP3K14 (0.47) PAK4PAK1PAK2PKN1PAK6
SCHEMBL1614344 0.90 CCNT1 (0.41) PAK4PAK1PAK2PKN1PAK6
SCHEMBL1826891 0.90 CCNT1 (0.41) PAK4PAK1PAK2PKN1PAK6
SCHEMBL12714670 0.90 CCNT1 (0.41) PAK4PAK1PAK2PKN1PAK6
SCHEMBL1614343 0.88 NPC1 (0.39) PAK4PAK1PAK2PKN1PAK6
SCHEMBL13575081 0.87 NPC1 (0.38) PAK4PAK1PAK2PKN1PAK6
SCHEMBL1613465 0.86 MAP3K14 (0.37) PAK4PAK1PAK2PKN1PAK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 — — EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 — — WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 PAK4 323/4885PAK1 144/4885PAK2 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback